WWWilma Wasco

Wilma Wasco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wilma Wasco has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Joseph Daniel Buxbaum

    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    5 shared publications
  • Nikhat F. Zaidi

    Department of Neurology, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease and Harvard Medical School, Charlestown, Massachusetts 02129, USA

    3 shared publications
  • Allen D Roses

    Department of Neurology, Duke University School of Medicine, United States

    1 shared publication
  • Annette C. Crowley

    From the ‡Genetics and Aging Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129 and the §Department of Psychiatry and Neurobiology, Mount Sinai School of Medicine, New York, New York 10029

    1 shared publication
  • Byungki Jang

    Ilsong Institute of Life Science, Hallym University, Seoul 07441, Republic of Korea

    1 shared publication
  • Christina Lilliehook

    From the ‡Genetics and Aging Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129 and the §Department of Psychiatry and Neurobiology, Mount Sinai School of Medicine, New York, New York 10029

    1 shared publication

Latest Publications

  • Open Access

    Calsenilin, a Presenilin Interactor, Regulates RhoA Signaling and Neurite Outgrowth

    by Hee-Jun Kim, Won-Haeng Lee, Mo-Jong Kim, Sunmee Shin, Byungki Jang, Jae-Bong Park, Wilma Wasco, Joseph D. Buxbaum, Yong-Sun Kim, Eun-Kyoung Choi

    Calsenilin modulates A-type potassium channels, regulates presenilin-mediated γ-secretase activity, and represses prodynorphin and c-fos genes expression. RhoA is involved in various cellular functions including proliferation, differentiation, migration, transcription, and regulation of the actin cytoskeleton. Although recent studies demonstrate that calsenilin can directly interact with RhoA and that RhoA inactivation is essential for neuritogenesis, it is uncertain whether there is a link between calsenilin and RhoA-regulated neuritogenesis. Here, we investigated the role of calsenilin in RhoA-regulated neuritogenesis using in vitro and in vivo systems. We found that calsenilin induced RhoA inactivation, which accompanied RhoA phosphorylation and the reduced phosphorylation levels of LIM kinase (LIMK) and cofilin. Interestingly, PC12 cells overexpressing either full-length (FL) or the caspase 3-derived C-terminal fragment (CTF) of calsenilin significantly inactivated RhoA through its interaction with RhoA and p190 Rho GTPase-activating protein (p190RhoGAP). In addition, cells expressing FL and the CTF of calsenilin had increased neurite outgrowth compared to cells expressing the N-terminal fragment (NTF) of calsenilin or vector alone. Moreover, Tat-C3 and Y27632 treatment significantly increased the percentage of neurite-bearing cells, neurite length, and the number of neurites in cells. Finally, calsenilin deficiency in the brains of calsenilin-knockout mice significantly interfered with RhoA inactivation. These findings suggest that calsenilin contributes to neuritogenesis through RhoA inactivation.


  • Editorial overview: Molecular & genetic basis of disease

    by Nancy M Bonini, Edward B Lee, Wilma Wasco, Allen D Roses

  • Open Access

    Calsenilin interacts with transcriptional co‐repressor C‐terminal binding protein(s)

    by Nikhat F. Zaidi, Kristy G. Kuplast, Kevin J. Washicosky, Yuji Kajiwara, Joseph D. Buxbaum, Wilma Wasco

    Calsenilin/potassium channel‐interacting protein (KChIP)3/ downstream regulatory element sequence antagonist modulator (DREAM) is a neuronal calcium‐binding protein that has been shown to have multiple functions in the cell, including the regulation of presenilin processing, repression of transcription and modulation of A‐type potassium channels. To gain a better understanding of the precise role of calsenilin in specific cellular compartments, an interactor hunt for proteins that bind to the N‐terminal domain of calsenilin was carried out. Using a yeast two‐hybrid system and co‐immunoprecipitation studies, we have identified the transcriptional co‐repressor C‐terminal binding protein (CtBP)2 as an interactor for calsenilin and have shown that the two proteins can interact in vivo. In co‐immunoprecipitation studies, calsenilin also interacted with CtBP1, a CtBP2 homolog. Our data also showed a calsenilin‐dependent increase in c‐fos protein levels in CtBP knockout fibroblasts, suggesting that CtBP may modulate the transcriptional repression of c‐fos by calsenilin. Furthermore, the finding that histone deacetylase protein and activity were associated with the calsenilin–CtBP immunocomplex suggests a mechanism by which calsenilin–CtBP may act to repress transcription. Finally, we demonstrated that calsenilin and CtBP are present in synaptic vesicles and can interact in vivo.


  • Intracellular calcium modulates the nuclear translocation of calsenilin

    by Nikhat F. Zaidi, Emma E. Thomson, Eun‐Kyoung Choi, Joseph D. Buxbaum, Wilma Wasco

    Calsenilin, which was originally identified as a presenilin interacting protein, has since been shown to be involved in the processing of presenilin(s), the modulation of amyloid β‐peptide (Aβ) levels and apoptosis. Subsequent to its original identification, calsenilin was shown to act as a downstream regulatory element antagonist modulator (and termed DREAM), as well as to interact with and modulate A‐type potassium channels (and termed KChIP3). Calsenilin is primarily a cytoplasmic protein that must translocate to the nucleus to perform its function as a transcriptional repressor. This study was designed to determine the cellular events that modulate the translocation of calsenilin from the cytoplasm to the nucleus. The nuclear translocation of calsenilin was found to be enhanced following serum deprivation. A similar effect was observed when cells were treated with pharmacological agents that directly manipulate the levels of intracellular calcium (caffeine and the calcium ionophore A23187), suggesting that the increased levels of calsenilin in the nucleus are mediated by changes in intracellular calcium. A calsenilin mutant that was incapable of binding calcium retained the ability to translocate to the nucleus. Taken together, these findings indicate that the level of intracellular calcium can modulate the nuclear translocation of calsenilin and that this process does not involve the direct binding of calcium to calsenilin.


  • Phosphorylation of calsenilin at Ser63 regulates its cleavage by caspase-3

    by E.K. Choi, J.S. Miller, N.F. Zaidi, E. Salih, J.D. Buxbaum, W. Wasco


  • Open Access

    Calsenilin Is a Substrate for Caspase-3 That Preferentially Interacts with the Familial Alzheimer's Disease-associated C-terminal Fragment of Presenilin 2

    by Eun-Kyoung Choi, Nikhat F. Zaidi, Janice S. Miller, Annette C. Crowley, David E. Merriam, Christina Lilliehook, Joseph D. Buxbaum, Wilma Wasco